News & Press Releases
Integrity Applications Spotlights GlucoTrack®Model DF-F Glucose Monitoring Device on World Diabetes Day 2013
November 14th, 2013
ASHKELON, Israel–(BUSINESS WIRE)–Integrity Applications, Inc. (OTCQB:IGAP), developer of the GlucoTrack®model DF-F non-invasive blood glucose measurement device, acknowledged World Diabetes Day 2013 today by spotlighting the potential of its device for painless blood glucose testing.
“I believe the device holds great potential to address the concerns of the millions of people with diabetes worldwide who must monitor their blood glucose level on a daily basis.”
“With its patented combination of ultrasonic, electromagnetic and thermal technologies, GlucoTrack provides clinically acceptable accuracy in blood glucose measurement,” said Avner Gal, President and CEO of Integrity Applications. “I believe the device holds great potential to address the concerns of the millions of people with diabetes worldwide who must monitor their blood glucose level on a daily basis.”
GlucoTrack features a small sensor that clips to the earlobe and measures the wearer’s blood glucose level by taking measurements using three technologies. The measurements are analyzed using a proprietary algorithm and displayed on, and verbally announced by, a small handheld device. The company has obtained a CE Mark for its GlucoTrack Model DF-F in Europe and intends to seek Food and Drug Administration approval for GlucoTrack in the United States.
To watch a video detailing the benefits of GlucoTrack, please visit the following link: http://www.youtube.com/watch?v=i9wtj179mq4
Led by the International Diabetes Federation and its member associations, World Diabetes Day is held on November 14 and is intended to engage millions of people worldwide in diabetes advocacy and awareness.
About Integrity Applications, Inc.
Integrity Applications, Inc. is a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes. Integrity Applications has developed the GlucoTrack model DF-F non-invasive glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level measurements without the pain, inconvenience, incremental cost, and difficulty of conventional (invasive) spot finger stick devices. Integrity Applications works primarily through its wholly-owned Israeli subsidiary, A.D. Integrity Applications, Ltd. For more information please visit www.integrity-app.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “intends,” and “believe,” are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect Integrity Applications’ actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Integrity Applications’ results include, but are not limited to, the ability of Integrity applications to successfully commercialize the GlucoTrack DF-F; the ability of the GlucoTrack DF-F to achieve acceptable pricing, adequate third party reimbursement or market acceptance; the ability of Integrity Applications to manage its growth and the expansion of its operations to include commercialization activities; risks relating to the use of third party manufacturers; risks relating to the development of Integrity Applications’ sales, marketing and distribution capability, either on its own or through collaborations with marketing partners; and the additional risk factors described in Integrity Applications’ filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2012.